GlassScriptPhysician profile
Kevin Deboer
NPI 1649272402
$2,019.96
in general payments reported to CMS, 2019-2025
27 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $82.66 · 2021: $80.08 · 2022: $353 · 2023: $269 · 2024: $578 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.55 |
| Education | $236.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $438.75 | 2021-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $223.77 | 2019-2025 | Dupixent |
| Insmed, INC. | $205.29 | 2019-2024 | Arikayce |
| Genzyme Corporation | $178.37 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $138.24 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $82.51 | 2022-2025 | Glassia |
| Grifols USA, LLC | $78.83 | 2024-2025 | Prolastin-C Liquid |
| Pfizer INC. | $77.83 | 2019-2020 | |
| United Therapeutics Corporation | $68.34 | 2019-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $53.98 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $49.93 | 2025 | Yupelri |
| Philips North America LLC | $48.44 | 2020-2023 | |
| Abbvie INC. | $44.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.79 | 2024-2025 | Ofev |
| Portola Pharmaceuticals, LLC | $40.73 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40.33 | 2023-2024 | Nucala, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $31.47 | 2024 | |
| Advanced Respiratory, INC | $27.78 | 2020 | |
| Vapotherm INC | $23.50 | 2023 | Vapotherm |
| Boston Scientific Corporation | $21.58 | 2023 | Exalt Model D |
| Baxter Healthcare | $19.39 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $18.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.34 | 2019 | |
| Gilead Sciences, INC. | $16.12 | 2022 | |
| Genentech USA, INC. | $15.61 | 2021 | |
| Breas Medical, INC. | $14.95 | 2023 | Vivo 45 Ls |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Deboer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.